周三,生物制药公司Sarepta Therapeutics续跌超20%,近两个交易日大跌超40%。该公司一季度的非公认会计准则(non-GAAP)每股亏损 3.42 美元,而去年同期每股盈利 0.72 美元,FactSet 调查的分析师预计盈利为 2.52 美元。营业收入从去年同期的约 4.14亿美元提升至 7.45亿美元,FactSet 调查的分析师预计为 6.88亿美元。
该公司将 2025 年净产品营业收入指引下调至 23亿至 26亿美元的区间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.